DUBLIN, April 15, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/4xgpn8/research_and) has announced the addition of the "Research and Development Forecast of China Heparin Industry to 2017" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Research and Development Forecast of China Heparin Industry to 2017 mainly analyzes the global and domestic market status quo of heparin industry, development conditions of heparin upstream and downstream industry, the supply and demand of major products, competitive pattern and business performance of domestic major enterprises; in the meanwhile, it makes the analysis and forecast of the future development of the heparin industry, offering the decisive reference for enterprises to know and invest the heparin industry.
The global heparin API manufacturing enterprises are mainly concentrated in the China, Europe and the US; the supply volume of heparin APIs of these three regions accounts for more than 95% of the global supply volume; the supply volume of heparin AIPs in China ranks the world first and accounts for more than 50% of the global supply volume.
According to the statistics of China Customs, since 2007, the export amount of China's heparin products has been rising greatly for a fourth consecutive year; in 2011, under the affection of depressed international market and the improvement of heparin export standards, the export volume and amount of China's heparin products had the obvious decline; in the year of 2012 and 2013, the decline trend of the export volume of heparin products slowed, but the export amount still had a certain decline because of the price.
At present, China has totally 22 heparin API manufacturing enterprises that have passed the approval of China Food and Drug Administration, but there are less than 10 manufacturers that have engaged in the actual production; in addition, there are 500 to 1,000 companies of heparin crude products, which form the high domestic heparin API production concentration ratio; the production capacity is mainly concentrated in the top five manufacturing enterprises of heparin products with about 80% of market shares totally now. Hepalink has the largest market shares of about 40% in the domestic market; the other major enterprises include Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Changzhou Qianhong Bio-pharma Co., Ltd., Yantai Dongcheng Biochemicals Co., Ltd. and Qingdao Jiulong Biomedicine Co., Ltd., while the downstream resource are inadequate.
Please note: The report is available immediately in Chinese. For the English version please allow 2 business days for translation.
Key Topics Covered:
1. Industry Overview of Heparin
2. China's Heparin Industry Development Environment
3. Development Overview of China's Heparin API (Active Pharmaceutical Ingredient) Industry
4. Development Overview of China's Heparin Upstream and Downstream Industry
5. China's Major Heparin Manufacturing Enterprises
6. Investment Analysis of Heparin Industry
7. Development Trends and Forecast of Heparin Industry
- Changzhou Qianhong Bio-pharma Co., Ltd.
- Development Prospects
- Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
- Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
- Qingdao Jiulong Biomedicine Co., Ltd.
- Shenzhen Hepalink Pharmaceutical Co., Ltd. (Hepalink)
- Tianjin Chase Sun Pharmaceutical Co., Ltd.
- Yantai Dongcheng Biochemicals Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/4xgpn8/research_and
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets